School of Nursing and Knight Cardiovascular Institute, Oregon Health & Science University, 3455 S.W. U.S. Veterans Hospital Road | Mail code: SN-ORD, Portland, OR 97239-2941, USA.
KU Leuven Department of Public Health and Primary Care, KU Leuven-University of Leuven, Leuven, Belgium.
Eur J Cardiovasc Nurs. 2024 Oct 21;23(7):818-824. doi: 10.1093/eurjcn/zvae020.
Incorporating biomarkers into cardiovascular studies, including nursing research, is a common approach when identifying underlying mechanisms and providing targets for intervention. However, effective utilization of biomarker data demands careful consideration. In the analysis, interpretation, and reporting phase, there are many facets to consider, including non-normality of the data, normalization procedures, and potential confounding influences of other clinical data. Furthermore, as many studies focus on patient-reported outcomes (PROs), it is important that the analysis and interpretation of biomarkers in relation to PROs is rigorous and reproducible. In this article, Part 2 of 2, we provide an overview of considerations for the analysis, interpretation, and reporting phases of biomarker studies. We also provide an example of these steps.
将生物标志物纳入心血管研究,包括护理研究,是在确定潜在机制和提供干预靶点时常用的方法。然而,要有效利用生物标志物数据需要仔细考虑。在分析、解释和报告阶段,有许多方面需要考虑,包括数据的非正态性、标准化程序以及其他临床数据的潜在混杂影响。此外,由于许多研究都集中在患者报告的结果(PROs)上,因此严格且可重复地分析和解释与 PROs 相关的生物标志物非常重要。在本文的第 2 部分(共 2 部分)中,我们概述了生物标志物研究的分析、解释和报告阶段的注意事项。我们还提供了这些步骤的一个示例。